JP2011520916A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520916A5
JP2011520916A5 JP2011509763A JP2011509763A JP2011520916A5 JP 2011520916 A5 JP2011520916 A5 JP 2011520916A5 JP 2011509763 A JP2011509763 A JP 2011509763A JP 2011509763 A JP2011509763 A JP 2011509763A JP 2011520916 A5 JP2011520916 A5 JP 2011520916A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
iss
composition according
decrease
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011509763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520916A (ja
JP5727367B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044192 external-priority patent/WO2009140626A2/en
Publication of JP2011520916A publication Critical patent/JP2011520916A/ja
Publication of JP2011520916A5 publication Critical patent/JP2011520916A5/ja
Application granted granted Critical
Publication of JP5727367B2 publication Critical patent/JP5727367B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011509763A 2008-05-15 2009-05-15 免疫賦活オリゴヌクレオチドを使用する長期疾患改良 Active JP5727367B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5360508P 2008-05-15 2008-05-15
US61/053,605 2008-05-15
PCT/US2009/044192 WO2009140626A2 (en) 2008-05-15 2009-05-15 Long term disease modification using immunostimulatory oligonucleotides

Publications (3)

Publication Number Publication Date
JP2011520916A JP2011520916A (ja) 2011-07-21
JP2011520916A5 true JP2011520916A5 (enExample) 2012-06-28
JP5727367B2 JP5727367B2 (ja) 2015-06-03

Family

ID=41258402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509763A Active JP5727367B2 (ja) 2008-05-15 2009-05-15 免疫賦活オリゴヌクレオチドを使用する長期疾患改良

Country Status (6)

Country Link
US (2) US8815817B2 (enExample)
EP (1) EP2300102B1 (enExample)
JP (1) JP5727367B2 (enExample)
AU (1) AU2009246169B2 (enExample)
CA (1) CA2724418A1 (enExample)
WO (1) WO2009140626A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002345847B2 (en) * 2001-06-21 2008-05-29 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
EP2007421A2 (en) * 2005-03-04 2008-12-31 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients.
CA2724418A1 (en) 2008-05-15 2009-11-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
US10946568B2 (en) 2011-06-09 2021-03-16 Rimtec Corporation Field joint coating material and a process for making a field joint
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
JP5800263B2 (ja) * 2011-09-27 2015-10-28 学校法人兵庫医科大学 アレルギー性鼻炎治療剤のスクリーニング方法およびその利用
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
CA2910584A1 (en) 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
US10322173B2 (en) * 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
WO2018039465A1 (en) * 2016-08-25 2018-03-01 Selecta Biosciences, Inc. Polyester polymer matrices for the delivery of allergens
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118802A (en) * 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en) * 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5015733A (en) * 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5093232A (en) * 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
EP0772619B2 (en) * 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1872786A1 (en) 1997-09-05 2008-01-02 The Regents of the University of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
SE9901257D0 (sv) 1999-04-09 1999-04-09 Hel Ab Behandling av smärta efter ledoperation
WO2000061151A2 (en) 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20040132677A1 (en) * 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
DE10230693A1 (de) 2002-07-06 2004-01-22 BSH Bosch und Siemens Hausgeräte GmbH Kühl-oder Gefriergerät
US7884083B2 (en) * 2002-08-12 2011-02-08 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
PT1575977E (pt) 2002-12-23 2009-12-15 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
EP2007421A2 (en) * 2005-03-04 2008-12-31 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients.
AU2007333368C1 (en) 2006-11-09 2014-03-13 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
CN101945666A (zh) * 2007-12-19 2011-01-12 Mivac发展股份公司 治疗自身免疫和过敏性疾病的组合物及方法
CA2724418A1 (en) 2008-05-15 2009-11-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides

Similar Documents

Publication Publication Date Title
JP2011520916A5 (enExample)
HRP20211398T1 (hr) Oralne formulacije citidinskih analoga i postupci njihove uporabe
HRP20210819T1 (hr) Fenfluramin za uporabu u liječenju dravet sindroma
JP2011528713A5 (enExample)
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
JP2009522370A5 (enExample)
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
WO2009051837A3 (en) Vaccine nanotechnology
WO2007070598A3 (en) Nucleotide and oligonucleotide prodrugs
JP2014507482A5 (enExample)
NO20076692L (no) Nanopartikulaere acetaminofenformuleringer
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
JP2008505857A5 (enExample)
IL202111A (en) Formulas for oral administration of amphotericin b and their use in the preparation of drugs for the treatment of infectious disease
Colombo et al. Microbiology of oral biofilm-dependent diseases: have we made significant progress to understand and treat these diseases?
JP2011527299A5 (enExample)
JP2009544665A5 (enExample)
JP2012503669A5 (enExample)
ES2748632T3 (es) Composición farmacéutica que comprende ácido propiónico para uso en el tratamiento de infecciones víricas
JP2012528856A5 (enExample)
JP2018524306A5 (enExample)
EP2700396A3 (en) Strip for the delivery of oral care compositions
Giyazova et al. CHANGES IN THE ORAL CAVITY IN PATIENTS WITH COVID 19 DISEASES
JP2008088189A5 (enExample)
JP2012097036A5 (enExample)